|
1
|
Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.
|
Hum Mutat
|
2007
|
3.93
|
|
2
|
Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen.
|
J Biol Chem
|
2001
|
2.88
|
|
3
|
Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates.
|
J Biol Chem
|
2008
|
1.92
|
|
4
|
Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan.
|
J Biol Chem
|
2002
|
1.67
|
|
5
|
Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly.
|
J Biol Chem
|
2003
|
1.36
|
|
6
|
Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.
|
Dev Dyn
|
2008
|
1.10
|
|
7
|
Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes.
|
Hum Mutat
|
2011
|
1.06
|
|
8
|
Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
|
Blood
|
2003
|
0.90
|
|
9
|
Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion.
|
J Cell Biochem
|
2008
|
0.88
|